334 related articles for article (PubMed ID: 34987640)
1. Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma.
Yang H; Berezowska S; Dorn P; Zens P; Chen P; Peng RW; Marti TM; Kocher GJ; Schmid RA; Hall SRR
Theranostics; 2022; 12(1):167-185. PubMed ID: 34987640
[No Abstract] [Full Text] [Related]
2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients.
Fusco N; Vaira V; Righi I; Sajjadi E; Venetis K; Lopez G; Cattaneo M; Castellani M; Rosso L; Nosotti M; Clerici M; Ferrero S
Lung Cancer; 2020 Dec; 150():53-61. PubMed ID: 33065463
[TBL] [Abstract][Full Text] [Related]
4. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
Okita R; Mimura-Kimura Y; Kawamoto N; Yamamoto N; Umeda M; Okada M; Inokawa H; Mimura Y; Murakami T; Nakata M; Okabe K
Cancer Immunol Immunother; 2023 Apr; 72(4):865-879. PubMed ID: 36115921
[TBL] [Abstract][Full Text] [Related]
5. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
de Perrot M; Wu L; Cabanero M; Perentes JY; McKee TD; Donahoe L; Bradbury P; Kohno M; Chan ML; Murakami J; Keshavjee S; Tsao MS; Cho BCJ
J Thorac Cardiovasc Surg; 2020 May; 159(5):2082-2091.e1. PubMed ID: 31866087
[TBL] [Abstract][Full Text] [Related]
6. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
7. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
[TBL] [Abstract][Full Text] [Related]
8. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
Qualiotto AN; Baldavira CM; Balancin M; Ab'Saber A; Takagaki T; Capelozzi VL
Front Immunol; 2023; 14():1268927. PubMed ID: 37901248
[TBL] [Abstract][Full Text] [Related]
10. Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer.
Wang L; Yang H; Dorn P; Berezowska S; Blank F; Wotzkow C; Marti TM; Peng RW; Harrer N; Sommergruber W; Kocher GJ; Schmid RA; Hall SRR
EBioMedicine; 2021 Nov; 73():103664. PubMed ID: 34740105
[TBL] [Abstract][Full Text] [Related]
11. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
[TBL] [Abstract][Full Text] [Related]
12. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
[TBL] [Abstract][Full Text] [Related]
13. Immune parameters associated with survival in metaplastic breast cancer.
Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response.
Yan J; Wu X; Zhu Y; Cang S
J Cancer Res Clin Oncol; 2023 Jan; 149(1):343-356. PubMed ID: 36595044
[TBL] [Abstract][Full Text] [Related]
15. Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.
Tazzari M; Brich S; Tuccitto A; Bozzi F; Beretta V; Spagnuolo RD; Negri T; Stacchiotti S; Deraco M; Baratti D; Camisaschi C; Villa A; Vergani B; Rivoltini L; Pilotti S; Castelli C
J Immunol Res; 2018; 2018():5804230. PubMed ID: 30510965
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P
Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208
[TBL] [Abstract][Full Text] [Related]
17. Immune Microenvironment in Gallbladder Adenocarcinomas.
Patil PA; Lombardo K; Cao W
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):557-563. PubMed ID: 33710123
[TBL] [Abstract][Full Text] [Related]
18. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
19. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
[TBL] [Abstract][Full Text] [Related]
20. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
